Omniox

Omniox is an IND-stage biotherapeutics company developing H-NOX platform technology into first-in-class oxygen delivery vehicles that address unmet medical needs where tissue hypoxia drives disease. The company's therapies target oncology, cardiovascular disease, trauma, diabetes, and sickle cell crises, with funding from the National Cancer Institute, the Wellcome Trust, and private investors.